Search Result
Results for "
glioblastoma cells
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
11
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-154954
-
|
OGM; GPR68-IN-1
|
GPR68
Ferroptosis
|
Inflammation/Immunology
Cancer
|
|
Ogremorphin (OGM) is a G protein coupled sensor GPR68 inhibitor with anti-inflammatory and anti-tumor activities. Ogremorphin can inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells .
|
-
-
- HY-P99908
-
|
NT-17
|
Interleukin Related
|
Cancer
|
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
-
- HY-B0114S2
-
|
GP 47680-d8
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
-
- HY-157975
-
|
|
Glutaminase
|
Cancer
|
|
LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state .
|
-
-
- HY-N8835
-
-
-
- HY-133570
-
|
|
HSP
ADC Payload
|
Cancer
|
|
17-AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. ADCs Toxin .
|
-
-
- HY-125964
-
|
|
Survivin
|
Cancer
|
|
LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM) .
|
-
-
- HY-152203
-
|
|
Others
|
Cancer
|
|
Mitochondrial respiration-IN-2 is the fluorine derivative of Virginiamycin M1 (HY-N6686). Mitochondrial respiration-IN-2 can inhibit mitochondrial translation of glioblastoma stem cells .
|
-
-
- HY-155532
-
|
|
Apoptosis
|
Cancer
|
|
10m/ZS44 is a blood-brain barrier-permeable Glioblastoma (GBM) inhibitor. 10m/ZS44 significantly inhibits GBM tumor growth in a mouse xenograft model. 10m/ZS44 also activates the SIRT1/p53-mediated apoptosis pathway, thereby inhibiting the proliferation of U251 cells .
|
-
-
- HY-152202
-
|
|
Mitochondrial Metabolism
|
Cancer
|
|
Mitochondrial respiration-IN-3 is the fluorine derivative of Dalfopristin (HY-A0241). Mitochondrial respiration-IN-3 has cell membrane-permeable. Mitochondrial respiration-IN-3 can inhibit mitochondrial translation of glioblastoma stem cells. Mitochondrial respiration-IN-3 can be used in research of cancer .
|
-
-
- HY-P99223
-
|
MEDI-575
|
PDGFR
|
Cancer
|
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
-
-
- HY-161946
-
|
|
Apoptosis
|
Cancer
|
|
GBM CSCs-IN-1 (Compound (−)-20), a derivative of rocaglate, is a potent inhibitor of glioblastoma stem cells (GBM CSCs) with an EC50 of 45 nM, functioning by targeting the RNA helicase DDX3. Furthermore, GBM CSCs-IN-1 is also capable of inducing apoptosis .
|
-
-
- HY-169884
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
MCI-INI-3 is a selective competitive inhibitor of human ALDH1A3 (with a Ki value of 0.55 μM for ALDH1A3 and a Ki value of 78.2 μM for ALDH1A1). MCIINI-3 inhibits the biosynthesis of retinoic acid and reduces the viability of GSC-83 and GSC-326 glioblastoma cells .
|
-
-
- HY-111449
-
BAY-218
1 Publications Verification
AHR antagonist 1
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
Cancer
|
|
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses .
|
-
-
- HY-146275
-
|
|
LXR
|
Cancer
|
|
LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .
|
-
-
- HY-170778
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-77 (Compound 15c) is a tubulin polymerization inhibitor that exerts anti-glioblastoma activity by inhibiting tubulin polymerization. Tubulin polymerization-IN-77 demonstrates significant blood-brain barrier permeability, effectively inducing G2/M phase arrest and triggering apoptosis in GBM cells, while also significantly inhibiting tumor cell migration .
|
-
-
- HY-159101
-
|
|
EGFR
PD-1/PD-L1
|
Cancer
|
|
EP26 is a potent and orally active EGFR and PD-L1 inhibitor with IC50 values of 48.6 nM, 1.77 µM, respectively. EP26 decreased the protein expression of p-EGFR. EP26 induces cell cycle arrest at G0/G1 phase. EP26 has the potential for the research of glioblastoma .
|
-
-
- HY-172586
-
|
|
GSK-3
PKA
|
Neurological Disease
Cancer
|
|
GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC50 s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC50 of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC50 : 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM .
|
-
-
- HY-148114
-
|
|
Autophagy
|
Cancer
|
|
MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-119624). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells .
|
-
-
- HY-173369
-
|
|
MAGL
Ligands for E3 Ligase
|
Cancer
|
|
PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis. (E3 ligase ligand: HY-128837; target protein ligand + linker: HY-173370; target protein inhibitor: HY-15249) .
|
-
-
- HY-19916A
-
|
BAL-101553 dihydrochloride
|
Microtubule/Tubulin
TNF Receptor
CTLA-4
PD-1/PD-L1
Checkpoint Kinase (Chk)
|
Cancer
|
|
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .
|
-
-
- HY-19916
-
|
BAL-101553
|
Microtubule/Tubulin
Checkpoint Kinase (Chk)
TNF Receptor
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .
|
-
-
- HY-12401A
-
|
|
Mps1
|
Cancer
|
|
Mps1-IN-3 hydrochloride is a potent and selective Mps1 inhibitor with an IC50 value of 50 nM. Mps1-IN-3 hydrochloride can inhibit the proliferation of glioblastoma cells, and effectively sensitizes glioblastomas to Vincristine in orthotopic glioblastoma xenograft model .
|
-
-
- HY-B0114
-
|
GP 47680
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-156266
-
|
Rhiz
|
Others
|
Cancer
|
|
Rhizochalinin (Rhiz) is a cytotoxic sphingolipid. Rhizochalinin (Rhiz) counteracts glioblastoma cell proliferation by inducing apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy. Rhizochalinin (Rhiz) can be used for human glioblastoma research .
|
-
-
- HY-147789
-
|
|
Akt
|
Neurological Disease
Cancer
|
|
FPDT is an anti-glioblastoma agent. FPDT displays the IC50 value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .
|
-
-
- HY-132863
-
-
-
- HY-132865
-
-
-
- HY-B0114S1
-
-
-
- HY-N12535
-
|
|
Others
|
Cancer
|
|
Tagitinin C is a sesquiterpenoid compound isolated from the Tithonia diversifolia. Tagitinin C has anticancer activity and can inhibit the proliferation of human glioblastoma U373 cells with an IC50 of 6.1 μg/mL. Tagitinin C can induce U373 cell death and be used in glioblastoma research .
|
-
-
- HY-B0114R
-
|
GP 47680 (Standard)
|
Reference Standards
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine (Standard) is the analytical standard of Oxcarbazepine. This product is intended for research and analytical applications. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-P4115
-
|
|
FABP
|
Cancer
|
|
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .
|
-
-
- HY-B0114S3
-
|
GP 47680-d10
|
Isotope-Labeled Compounds
Apoptosis
Sodium Channel
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S
-
|
GP 47680-d4
|
Isotope-Labeled Compounds
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-122910
-
|
|
Apoptosis
|
Cancer
|
|
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤500 nM .
|
-
-
- HY-160054
-
-
-
- HY-174338
-
-
-
- HY-19345A
-
|
NSC13316 dihydrochloride
|
p38 MAPK
|
Cancer
|
|
Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .
|
-
-
- HY-19345
-
|
NSC13316
|
p38 MAPK
|
Cancer
|
|
Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .
|
-
-
- HY-13610B
-
|
|
Caspase
|
Cancer
|
|
N1,N11-Diethylnorspermine hydrobromide is a potent anticancer agent. N1,N11-Diethylnorspermine hydrobromide is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine hydrobromide induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine hydrobromide kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
|
-
-
- HY-N0610A
-
|
3-Phenylacrylic acid; β-Phenylacrylic acid
|
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
-
- HY-160057
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
GMT 8 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity. GMT 4 aptamer sodium also shows high binding affinity to the T lymphocyte cell line CCRF-CEM .
|
-
-
- HY-159580
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .
|
-
-
- HY-116165
-
|
|
Phospholipase
|
Cancer
|
|
ML298 is a potent and selective inhibitor of Phospholipase D2 (PLD2) with an IC50 of 355 nM. ML298 decreases invasive migration in U87-MG glioblastoma cells .
|
-
-
- HY-14590
-
-
-
- HY-115690
-
|
|
Drug Derivative
|
Cancer
|
|
K-TMZ is a derivative of methyl ketone, which exhibits antitumor efficacy against O 6 -methylguanine DNA methyltransferase (MGMT) deficient cell. K-TMZ can be used for research of glioblastoma .
|
-
-
- HY-124582
-
NEO214
1 Publications Verification
|
Autophagy
mTOR
|
Cancer
|
|
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
|
-
-
- HY-149374
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 36 (Compound 10) is a novel and potent tubulin inhibitor and inhibits the polymerization of microtubular protein then induces apoptosis with an IC50 value of 1.5±0.1 μM. Tubulin inhibitor 36 (Compound 10) has significant anti-mitotic effect and exhibits activities against glioblastoma cells. Tubulin inhibitor 36 (Compound 10) has anti-tumor effects and can be used for glioblastoma multiforme (GBM) research .
|
-
-
- HY-161256
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells .
|
-
-
- HY-163121
-
|
|
Glycosyltransferase
|
Cancer
|
|
PST3.1a is a N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with the IC50 of 2 μM. PST3.1a inhibits glioblastoma-initiating cell invasiveness and proliferation .
|
-
- HY-N0610AS
-
|
3-Phenylacrylic acid-d6; β-Phenylacrylic acid-d6
|
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
- HY-142683
-
|
|
Phosphatase
|
Neurological Disease
Cancer
|
|
SCP1-IN-2 (Compound SH T-65) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-2 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-2 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity .
|
-
- HY-142682
-
|
|
Phosphatase
|
Neurological Disease
Cancer
|
|
SCP1-IN-1 (compound SH T-62) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-1 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-1 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity .
|
-
- HY-168899
-
|
|
FAK
Apoptosis
|
Cancer
|
|
FAK-IN-24 (Compound 9f) is a FAK inhibitor (IC50: 0.815 nM). FAK-IN-24 induces DNA damage and apoptosis. FAK-IN-24 has anti-glioblastoma activity. FAK-IN-24 inhibits proliferation of glioblastoma cell lines U87-MG (IC50 = 15 nM) and U251 (IC50 = 20 nM). FAK-IN-24 inhibits tumor growth in U87-MG xenograft model .
|
-
- HY-158197
-
|
|
Sigma Receptor
Proteasome
|
Cancer
|
|
RC-106 is a proteasome inhibitor (IC50: 35 μM) and Sigma receptor modulator with anticancer activity. RC-106 has antiproliferative activity against cancer cells including glioblastoma (GB) and multiple myeloma (MM) .
|
-
- HY-N0610AR
-
|
3-Phenylacrylic acid (Standard); β-Phenylacrylic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid (Standard) is the analytical standard of Cinnamic acid. This product is intended for research and analytical applications. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
- HY-163835
-
|
|
Ephrin Receptor
|
Cancer
|
|
UniPR1454 targets EphA2 receptor, inhibits the EphA2-ephrin A1 interaction with an IC50 of 2.6 μM. UniPR1454 inhibits the proliferation of glioblastoma cell U251 .
|
-
- HY-W018326
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Temozolomide acid is a carboxylic acid derivative of Temozolomide (HY-17364) with anticancer activity. Temozolomide is a DNA alkylating agent, methylating the guanine and adenine bases of DNA, causing breaks in DNA double strand, cell cycle arrest, and eventually cell death. Temozolomide acid is promising for research of glioblastoma and brain cancer .
|
-
- HY-133717
-
|
|
Opioid Receptor
TRP Channel
|
Cancer
|
|
Naltriben is a selective δ2-opioid receptor antagonist and TRPM7 activator. Naltriben enhances glioblastoma cell migration and invasion. Naltriben can be used in research into neurological diseases and cancer .
|
-
- HY-116273
-
|
|
Phospholipase
|
Cancer
|
|
ML299 is a selective allosteric modulator and a dual inhibitor of phospholipases D1 and D2 (IC50 values are 6 and 12 nM, respectively). ML299 decreases invasive migration in U87-MG glioblastoma cells .
|
-
- HY-174406
-
-
- HY-153708
-
|
CAF-170
|
CDK
|
Cancer
|
|
SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. SGC-CLK-1 can inhibit the growth of melanoma and glioblastoma cells .
|
-
- HY-14590R
-
|
Kempferol(Standard); Robigenin (Standard)
|
Reference Standards
Estrogen Receptor/ERR
Autophagy
Mitophagy
Apoptosis
HIV
Parasite
Endogenous Metabolite
|
Cancer
|
|
Kaempferol (Standard) is the analytical standard of Kaempferol. This product is intended for research and analytical applications. Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .
|
-
- HY-147637
-
|
|
Ephrin Receptor
|
Cancer
|
|
EphA2 agonist 1 (Compound 7bg) is a potent EphA2 receptor agonist. EphA2 agonist 1 shows great potency and selectivity toward EphA2 overexpressed glioblastoma cells and stimulates EphA2 phosphorylation .
|
-
- HY-N0421
-
|
Cinobufagine
|
Apoptosis
|
Neurological Disease
Cancer
|
|
Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-149530
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-86 (compound 4i) is an EGFR inhibitor (IC50: 1.5 nM) with high activity against glioblastoma. EGFR-IN-86 induces apoptosis and arrests the U87 cell cycle in the G2/M phase .
|
-
- HY-12616
-
|
|
LPL Receptor
|
Cancer
|
|
ACT-209905 is a S1P1 receptor agonist. ACT-209905 can inhibit glioblastoma (GBM) cell growth and migration. ACT-209905 also has immunomodulating activity, and can be used in research of autoimmune diseases .
|
-
- HY-B0106
-
|
UCB L059
|
DNA Methyltransferase
|
Neurological Disease
Cancer
|
|
Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
- HY-162478
-
|
|
Phosphatase
|
Cancer
|
|
GR-28 is an inhibitor for small C-terminal domain phosphatase 1 (SCP1). GR-28 inhibits the transcriptional activity of repressor element-1 silencing transcription factor (REST), inhibits the proliferation of glioblastoma cells (IC50 is 2.9 and 10.1 µM, for cells A172 and T98G) .
|
-
- HY-126771
-
|
Chr-A
|
Antibiotic
Bacterial
Akt
GSK-3
β-catenin
c-Myc
|
Infection
Cancer
|
|
Chrysomycin A (Chr-A), an antibiotic, can be obtained from Streptomyces. Chrysomycin A exhibits antitumor and anti-tuberculous and MRSA activities. As for glioblastoma, Chrysomycin A inhibits the proliferation, migration, and invasion of cancer cells through the Akt/GSK-3β/β-catenin signaling pathway .
|
-
- HY-N2599
-
|
|
COX
Apoptosis
|
Cancer
|
|
Taraxerol acetate is a COX-1 and COX-2 inhibitor with IC50 values of 116.3 μM and 94.7 μM, respectively. Taraxerol acetate the has the anticancer potential and induces cell apoptosis .
|
-
- HY-149375
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 37 (Compound 12) is a Tubulin inhibitor that can effectively inhibit Tubulin aggregation (IC50=1.3 µM). Tubulin inhibitor 37 exhibits antiproliferative activity against human tumor cell lines and has potential for studying cancer .
|
-
- HY-108476
-
INDY
2 Publications Verification
|
DYRK
|
Cancer
|
|
INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC50s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a Ki value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .
|
-
- HY-N3001
-
|
|
STAT
VEGFR
Bcl-2 Family
Survivin
IAP
NF-κB
Apoptosis
Caspase
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
|
-
- HY-146320
-
|
|
Chloride Channel
|
Cancer
|
|
ANO1-IN-1 (Compound 9c) is a selective ANO1 channel blocker with an IC50 of 2.56 μM and 15.43 μM against ANO1 and ANO2, respectively. ANO1-IN-1 suppresses strongly proliferation of glioblastoma cells .
|
-
- HY-P10782
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
|
Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
|
-
- HY-146321
-
|
|
Chloride Channel
|
Cancer
|
|
ANO1-IN-2 (Compound 10q) is a selective ANO1 channel blocker with an IC50 of 1.75 μM and 7.43 μM against ANO1 and ANO2, respectively. ANO1-IN-2 suppresses strongly proliferation of glioblastoma cells .
|
-
- HY-N0610AS2
-
|
3-Phenylacrylic acid-13C3; β-Phenylacrylic acid-13C3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid- 13C3 (3-Phenylacrylic acid- 13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .
|
-
- HY-153268
-
|
BDTX-1535; EGFR-IN-76
|
EGFR
|
Cancer
|
|
BDTX-1535 (EGFR-IN-76) is an orally available, blood-brain permeable, selective EGFR inhibitor with anti-tumor activity. BDTX-1535 is indicated in a variety of models including non-small cell lung cancer, glioblastoma patient-derived tumors, and intracranial tumors .
|
-
- HY-111187
-
|
KX-02
|
Src
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell .
|
-
- HY-12456
-
|
|
Antibiotic
ADC Payload
DNA Alkylator/Crosslinker
Necroptosis
Apoptosis
|
Cancer
|
|
Duocarmycin SA is an orally active antitumor antibiotic with an IC50 of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .
|
-
- HY-114413
-
|
|
HSP
Apoptosis
|
Cancer
|
|
YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to heat shock protein 90 (HSP90) with an IC50 of 820 nM on NFAT nuclear translocation. YZ129-induced GBM cell-cycle arrest at the G2/M phase promotes apoptosis and inhibited tumor cell proliferation and migration .
|
-
- HY-149515
-
|
|
Monoamine Oxidase
|
Cancer
|
|
MAO-IN-3 (Compound 5) is a reversible and competitive MAO inhibitor (Ki: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC50 of 0.8 μM. MAO-IN-3 can be used for cancer research .
|
-
- HY-W040150
-
|
|
LXR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux , inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells .
|
-
- HY-163290
-
|
|
Fluorescent Dye
Monoamine Oxidase
|
Cancer
|
|
HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis .
|
-
- HY-N0421R
-
|
Cinobufagine (Standard)
|
Reference Standards
Apoptosis
|
Neurological Disease
Cancer
|
|
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-14266A
-
|
|
Apoptosis
Reverse Transcriptase
Autophagy
HIV
|
Infection
|
|
Dapivirine hydrochloride is a non-nucleoside reverse transcriptase inhibitor with antitumor activity. Dapivirine hydrochloride attenuates the proliferation of glioblastoma cells and induces apoptosis. Dapivirine hydrochloride modulates autophagy and activates Akt, Bad, and SAPK/JNK signaling pathways. Dapivirine hydrochloride has shown inhibitory effects on glioma cell growth both in vitro and in vivo. Dapivirine hydrochloride is also a promising drug candidate for topical microbial agents for the prevention of sexual transmission of HIV-1 .
|
-
- HY-W747797
-
|
|
Isotope-Labeled Compounds
Apoptosis
|
Cancer
|
|
Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-112293
-
|
|
EGFR
|
Cancer
|
|
GW2974 is a potent dual inhibitor of EGFR and HER2 with IC50 value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the EGFR and HER2 and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .
|
-
- HY-B0106S
-
|
UCB L059-d6
|
Isotope-Labeled Compounds
DNA Methyltransferase
|
Neurological Disease
Cancer
|
|
Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
- HY-B0106S1
-
|
UCB L059-d3
|
DNA Methyltransferase
|
Neurological Disease
Cancer
|
|
Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
- HY-115670
-
|
|
MMP
|
Inflammation/Immunology
Cancer
|
|
GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC50s of 8.0 nM and 11.5 nM, respectively . ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells .
|
-
- HY-101302
-
|
|
Opioid Receptor
TRP Channel
|
Inflammation/Immunology
|
|
Naltriben mesylate is a potent δ2-opioid receptor antagonist and a TRPM7 activator. Naltriben mesylate shows Ki values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer .
|
-
- HY-129440
-
|
|
PDGFR
ERK
Caspase
|
Metabolic Disease
Inflammation/Immunology
|
|
N-(p-Coumaroyl) Serotonin is a selective inhibitor of PDGFRβ, ERK1/2 and caspase-8 with antioxidant, anti-atherosclerotic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits glioblastoma cells (U251MG, T98G) with IC50 of 48-81 μM, while the IC50 for normal fibroblasts is 181-197 μM. N-(p-Coumaroyl) Serotonin inhibits PDGF signaling (reducing receptor phosphorylation), blocks Ca 2+ influx, and induces apoptosis (activating caspase-8). N-(p-Coumaroyl) Serotonin can improve atherosclerosis and aortic wall enlargement, and can also be used in the study of glioblastoma .
|
-
- HY-115567
-
|
1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole
|
Apoptosis
|
Cancer
|
|
5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model .
|
-
- HY-B0106R
-
|
UCB L059 (Standard)
|
Reference Standards
DNA Methyltransferase
|
Neurological Disease
Cancer
|
|
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
- HY-12772R
-
|
Itraconazole metabolite Hydroxy Itraconazole (Standard); R-63373 (Standard)
|
Reference Standards
Fungal
Drug Metabolite
|
Others
|
|
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
- HY-149145
-
-
- HY-112158
-
|
ERGi-USU
|
Ser/Thr Kinase
|
Cancer
|
|
NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling .
|
-
- HY-P10795
-
|
Antibiotic NK 2
|
Parasite
Bacterial
Fungal
|
Infection
|
|
NK-2 (Antibiotic NK 2), a shortened linear amphipathic NK-Lysin analog (comprising residues 39 to 65 of NK-lysin), is an antimicrobial peptide that exhibits potent activities against trypanosoma cruzi, Candida albicans, gram-positive and gram-negative bacteria. NK-2 can kill trypanosomes residing inside the human glioblastoma cell line 86HG39, left the host cells apparently unharmed .
|
-
- HY-172659
-
|
MHO7
|
Fungal
Akt
Apoptosis
|
Cancer
|
|
6-Epi-ophiobolin G (MHO7), a Marine-derived fungal metabolite, is a blood-brain barrier penetrated and orally active Akt inhibitor. 6-Epi-ophiobolin G (MHO7) inhibits GBM cell proliferation and promotes apoptosis. 6-Epi-ophiobolin G (MHO7) can be used in the research for glioblastoma .
|
-
- HY-P10928A
-
|
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
BCY17901 is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
|
-
- HY-162090
-
|
|
TRP Channel
|
Cancer
|
|
TRPC antagonist 1 (compound 15g) is a potent TRP channel (TRPC) antagonist with IC50s of 2.4 μM, 12.2 μM, 7.6 μM, 2.9 μM, and 3.4 μM for TRPC3, TRPC4, TRPC5, TPRC6, and TRPC7, respectively. TRPC antagonist 1 displays noteworthy anti-glioblastoma efficacy in vitro against U87 cell lines .
|
-
- HY-153627
-
|
|
Deubiquitinase
|
Cancer
|
|
G13KS is a deubiquitinase UCHL1 ligand and inhibitor. G13KS inhibits recombinant and cellular UCHL1. G13KS reduces levels of monoubiquitin in human glioblastoma cells . GK13S is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-170907
-
|
|
HDAC
DNA/RNA Synthesis
RAD51
|
Cancer
|
|
HDAC-IN-85 (Compound 1) is a BBB-permeable HDAC inhibitor. HDAC-IN-85 has an inhibitory effect on brain tumor cell lines. HDAC-IN-85 can induce acetylation, leading to DNA double-strand breaks, and induce the ubiquitination of RAD51, disrupting the DNA repair process. HDAC-IN-85 can be used in the research of glioblastoma .
|
-
- HY-P10928
-
|
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
|
-
- HY-B0688S
-
|
4,4′-Diaminodiphenyl sulfone-d8; DDS-d8
|
Antibiotic
Parasite
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
Inflammation/Immunology
Cancer
|
|
Dapsone-d8 is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases .
|
-
- HY-10261B
-
|
(E/Z)-BIBW 2992
|
EGFR
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
Autophagy
|
Others
Cancer
|
|
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
|
-
- HY-115925
-
|
|
SHP2
Phosphatase
|
Cancer
|
|
SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo .
|
-
- HY-100155
-
|
|
Sigma Receptor
Apoptosis
Autophagy
|
Cancer
|
|
4-IBP is a selective σ₁ receptor agonist with high affinity for the σ₁ receptor (Ki =1.7 nM) and moderate affinity for the σ₂ receptor (Ki = 25.2 nM). 4-IBP can make cancer cells more sensitive to the cytotoxic effects of pro-apoptotic and pro-autophagic compounds. 4-IBP significantly reduces the migration ability of a variety of cancer cells. 4-IBP is mainly used in glioblastoma, non-small cell lung cancer and prostate cancer research .
|
-
- HY-103407
-
|
|
Dopamine Receptor
|
Neurological Disease
Cancer
|
|
PD 168568 is a orally active and potent dopamine receptor D4 (DRD4) antagonist. PD 168568 contains an isoindolinone and is selective for the D4 receptor versus D2 and D3, with Ki values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research .
|
-
- HY-19939S
-
VX-984
4 Publications Verification
M9831
|
DNA-PK
|
Cancer
|
|
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .
|
-
- HY-120896B
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Imipramine Blue chloride is a potent anti-invasive agent. Imipramine Blue chloride inhibits the invasion of glioma. Imipramine Blue chloride inhibits NADPH oxidase-mediated reactive oxygen species generation .
|
-
- HY-174212
-
|
|
Apoptosis
|
Cancer
|
|
MXC-017 is a blood-brain barrier (BBB)-penetrant apoptosis inducer that directly targets Vimentin (VIM). MXC-017 prevents radiation-induced glioma stem cell (GSC) formation, while promoting G0/G1 cell cycle arrest and apoptosis. MXC-017 exhibits minimal off-target effects and shows no significant cytotoxicity. MXC-017 significantly prolongs median survival when used in combination with radiation therapy in glioblastoma (GBM) mouse models.
|
-
- HY-148833
-
|
|
MDM-2/p53
|
Cancer
|
|
MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
|
-
- HY-171852
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Iodoquine is an analog of chloroquine. Iodoquine exhibits high uptake in tumor cells and can localize to cells with high ALDH1 content, including cancer stem cells. With low uptake in normal brain tissue, iodoquine can be used in research related to tumor diagnosis or as a radiotracer .
|
-
- HY-170577
-
|
|
Pyruvate Kinase
Apoptosis
|
Cancer
|
|
PKM2-IN-8 (Compound 9b) is a pyruvate kinase M2 (PKM2) inhibitor (IC50 = 0.31 μM). PKM2-IN-8 has potent antiproliferative activity against U87MG glioma cells. PKM2-IN-8 can induce early apoptosis and reduce lactate levels. PKM2-IN-8 can be used for the research of glioblastoma .
|
-
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
- HY-161155
-
|
|
HDAC
|
Inflammation/Immunology
|
|
HDAC6-IN-31 (compound 8m) is a selective HDAC6 inhibitor, with the IC50 value of 0.026 μM, that significantly inhibits the production and release of pro-inflammatory cytokines. While HDAC6 is critically involved in the activation of inflammasomes, HDAC6-IN-31 has the potential to inhibit NLRP3 inflammasome-driven inflammatory diseases. HDAC6-IN-31 also inhibits glioblastoma cell migration .
|
-
- HY-P3103
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa suppresses glioblastoma cell proliferation in vitro and in vivo .
|
-
- HY-150309
-
|
|
PI3K
|
Cancer
|
|
PI3K-IN-54 (compound 10w) is a pan-PI3K inhibitor. The IC50 values of PI3K-IN-54 for p110α, p110β, and p110δ are 0.22 nM, 1.4 nM, and 0.38 nM, respectively. PI3K-IN-54 can be used in cancer research .
|
-
- HY-100475
-
|
|
Apoptosis
MDM-2/p53
Prolyl Endopeptidase (PREP)
|
Cancer
|
|
KYP-2047 is a potent and BBB-penetrating prolyl-oligopeptidase (POP) inhibitor, with an Ki value of 0.023 nM. KYP-2047 reduces glioblastoma proliferation through angiogenesis and apoptosis modulation .
|
-
- HY-17595
-
|
|
Parasite
Apoptosis
Microtubule/Tubulin
|
Infection
Cancer
|
|
Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .
|
-
- HY-17595R
-
|
|
Reference Standards
Parasite
Apoptosis
Microtubule/Tubulin
|
Infection
Cancer
|
|
Mebendazole (Standard) is the analytical standard of Mebendazole. This product is intended for research and analytical applications. Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .
|
-
- HY-W087830
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
|
-
- HY-103693
-
NAZ2329
3 Publications Verification
|
Phosphatase
|
Cancer
|
|
NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC50=7.5 µM for hPTPRZ1) and PTPRG (IC50=4.8 µM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC50 of 1.1 µM) than the whole intracellular (D1 + D2) fragment (IC50 of 7.5 µM). NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells and suppress stem cell-like properties .
|
-
- HY-124068
-
|
|
Apoptosis
GSK-3
MMP
Reactive Oxygen Species (ROS)
|
Infection
Inflammation/Immunology
Cancer
|
LQB-118 is an orally active compound derived from sandalwood. LQB-118 can inhibit the migration of glioblastoma cells and induce cell death. LQB-118 can suppress the migration and invasion of prostate cancer cells by regulating the AKT/GSK3β pathway and the expression of the MMP-9/reck genes. LQB-118 can also inhibit yeast polysaccharide-induced inflammation both in vivo and in vitro. Additionally, LQB-118 selectively induces ROS-triggered and mitochondrial-dependent apoptosis in Leishmania amazonensis. LQB-118 can be used in studies related to inflammation, infections, and cancer diseases .
|
-
- HY-101349
-
|
|
Dopamine Receptor
Apoptosis
|
Neurological Disease
Cancer
|
|
L 741742 is a dopamine receptor D4 (DRD4) antagonist that selectively inhibits glioblastomas (GBM) growth in vitro and in vivo, synergyed with Temozolomide (TMZ) (HY-17364). L 741742 disrupts in effectors PDGFRβ/ERK1/2 and mTOR signaling. Additionally, L 741742 disrupts endolysosmal function compromising the autophagy-lysosomal degradation pathway, followed by G0/G1 cell cycle arrest and Apoptosis. L 741742 is promising for research of GBM and neurogenesis .
|
-
- HY-10261BR
-
|
(E/Z)-BIBW 2992 (Standard)
|
EGFR
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
Autophagy
Reference Standards
|
Others
|
|
(E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
|
-
- HY-P3103A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa TFA, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa TFA directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa TFA suppresses glioblastoma cell proliferation in vitro and in vivo .
|
-
- HY-115630
-
|
|
RIP kinase
Caspase
Apoptosis
|
Cancer
|
|
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .
|
-
- HY-176556
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-1671 is a selective EGFR inhibitor with an IC50 of 0.19 nM. EGFR-IN-167 exhibits good potency against various EGFR mutants (IC50 = 0.109 nM, 0.75 nM and <0.05 nM against EGFR (L858R), EGFR (C797S) and EGFR (del19), respectively). EGFR-IN-1671 covalently engages the catalytically conserved lysine of EGFR in live mammalian cells. EGFR-IN-1671 demonstrates excellent anti-proliferative activity by inhibiting EGFR autophosphorylation. EGFR-IN-1671 can be used for the study of non-small-cell lung carcinomas (NSCLC), glioblastoma and many solid tumors .
|
-
- HY-155889
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
|
-
- HY-168883
-
|
|
Apoptosis
Pyruvate Kinase
|
Cancer
|
|
PKM2 modulator 2 (compound C599) is a potent PKM2 inhibitor. PKM2 modulator 2 shows antiproliferative activity. PKM2 modulator 2 induces apoptosis. PKM2 modulator 2 has the potential for the research of glioblastoma .
|
-
- HY-155888
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
|
-
- HY-168882
-
|
|
Apoptosis
Pyruvate Kinase
|
Cancer
|
|
PKM2 modulator 1 (compound C998) is a potent PKM2 inhibitor. PKM2 modulator 1 shows antiproliferative activity. PKM2 modulator 1 induces apoptosis. PKM2 modulator 1 has the potential for the research of glioblastoma .
|
-
- HY-136484
-
|
|
FLAP
|
Cancer
|
|
FEN1-IN-3 (Compound 4) is a human flap endonuclease-1 (hFEN1) inhibitor. FEN1-IN-3 stabilizes hFEN1 with an EC50 of 6.8 μM .
|
-
- HY-B1334A
-
|
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
- HY-B1334
-
|
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
|
-
- HY-117357
-
|
|
SGK
|
Cancer
|
|
SI-113 is a SGK1 inhibitor, with an IC50 of 600 nM. SI113 induces autophagy .
|
-
- HY-B1334AR
-
|
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Perhexiline (maleate) (Standard) is the analytical standard of Perhexiline (maleate). This product is intended for research and analytical applications. Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
- HY-136485
-
|
|
FLAP
|
Cancer
|
|
FEN1-IN-4 (Compound 2) is a human flap endonuclease-1 (hFEN1) inhibitor .
|
-
- HY-137441
-
|
PU-HZ151
|
HSP
|
Neurological Disease
Cancer
|
|
Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
|
-
- HY-137441A
-
|
PU-HZ151 hydrochloride
|
HSP
|
Neurological Disease
Cancer
|
|
Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
|
-
- HY-170405
-
|
|
PROTACs
mTOR
|
Cancer
|
|
YB-3-17 is a bifunctional molecule, that inhibits mTOR (IC50=0.22 nM) or degrades G1 to S phase transition 1 gene (GSPT1, DC50=5 nM) in a PROTAC mechanism. YB-3-17 exhibits antiproliferative activity in multi glioblastoma cell lines with IC50 of nanomolare levels. YB-3-17 exhibits antitumor efficacy in mouse models . (Pink: ligand for target protein (HY-170407); Black: linker (HY-A0102); Blue: ligand for E3 ligase Cereblon (HY-14658))
|
-
- HY-117991
-
|
|
VEGFR
|
Cancer
|
|
DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
|
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combinated with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for research on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
- HY-162384
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .
|
-
- HY-155577
-
|
|
Monoamine Oxidase
HSP
|
Cancer
|
|
MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC50 value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research .
|
-
- HY-120115
-
|
Olaparib-bodipy FL
|
PARP
Fluorescent Dye
|
Cancer
|
|
PARPi-FL (Olaparib-bodipy FL) is a small-molecule fluorescent inhibitor of PARP1 that can specifically bind to PARP1. PARPi-FL can be used as a fluorescent imaging agent for tumor detection, diagnosis, and surgical guidance .
|
-
- HY-N0103A
-
|
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-N0103
-
|
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
PTEN
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-N0103R
-
|
|
Reference Standards
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-124813
-
|
113B7
|
FAK
EGFR
MMP
|
Cancer
|
|
PDZ1i is a potent, BBB-penetrated and specific MDA-9/Syntenin inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving FAK and EGFRvIII. PDZ1i reduces MMP secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion .
|
-
- HY-155580
-
|
|
Monoamine Oxidase
HSP
|
Cancer
|
|
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
|
-
- HY-13260
-
|
|
Akt
Autophagy
Apoptosis
|
Cancer
|
|
CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC50=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). Antitumor activity.
|
-
- HY-13260A
-
|
|
Akt
Autophagy
Apoptosis
|
Cancer
|
|
CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .
|
-
- HY-13610
-
|
|
Caspase
mTOR
|
Cancer
|
|
N1,N11-Diethylnorspermine (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
|
-
- HY-13610A
-
|
DENSPM tetrahydrochloride; BENSPM tetrahydrochloride
|
Caspase
mTOR
|
Cancer
|
|
N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine tetrahydrochloride activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine tetrahydrochloride induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
|
-
- HY-13610AR
-
|
|
Caspase
mTOR
|
Cancer
|
|
N1,N11-Diethylnorspermine (tetrahydrochloride) (Standard) is the analytical standard of N1,N11-Diethylnorspermine (tetrahydrochloride). This product is intended for research and analytical applications. N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine tetrahydrochloride activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine tetrahydrochloride induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
|
-
- HY-120267
-
-
- HY-147011
-
|
|
Fat Mass and Obesity-associated Protein (FTO)
|
Cancer
|
|
FTO-IN-7 (compound 17) is an inhibitor of FTO (fat mass and obesity-associated protein) with an IC50 of <1 μM. FTO-IN-7 can be used for the study of small-cell lung cancers and human bone marrow striated muscle cancer .
|
-
- HY-146669
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
BChE-IN-6 (compound 12) is a potent BChE inhibitor, with a Ki of 0.182 μM. BChE-IN-6 shows chelating capacity on Zn 2+. BChE-IN-6 can be used for Alzheimer’s disease (AD) research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W087830
-
|
|
Biochemical Assay Reagents
|
|
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10928
-
|
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
|
-
- HY-P4115
-
|
|
FABP
|
Cancer
|
|
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .
|
-
- HY-P10782
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
|
Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
|
-
- HY-P10795
-
|
Antibiotic NK 2
|
Parasite
Bacterial
Fungal
|
Infection
|
|
NK-2 (Antibiotic NK 2), a shortened linear amphipathic NK-Lysin analog (comprising residues 39 to 65 of NK-lysin), is an antimicrobial peptide that exhibits potent activities against trypanosoma cruzi, Candida albicans, gram-positive and gram-negative bacteria. NK-2 can kill trypanosomes residing inside the human glioblastoma cell line 86HG39, left the host cells apparently unharmed .
|
-
- HY-P10928A
-
|
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
BCY17901 is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
|
-
- HY-P3103
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa suppresses glioblastoma cell proliferation in vitro and in vivo .
|
-
- HY-P3103A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PINT-87aa TFA, an 87-amino acid (aa) peptide, is encoded by the circular form of the long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT). PINT-87aa TFA directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes. PINT-87aa TFA suppresses glioblastoma cell proliferation in vitro and in vivo .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99908
-
|
NT-17
|
Interleukin Related
|
Cancer
|
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
- HY-P99223
-
|
MEDI-575
|
PDGFR
|
Cancer
|
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99806
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research .
|
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combinated with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for research on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N12535
-
-
-
- HY-N0610A
-
-
-
- HY-14590
-
-
-
- HY-14590R
-
-
-
- HY-N0421
-
-
-
- HY-N3001
-
-
-
- HY-N8835
-
-
-
- HY-N0610AR
-
-
-
- HY-N2599
-
-
-
- HY-N0421R
-
|
Cinobufagine (Standard)
|
Structural Classification
Animals
Source classification
Steroids
|
Reference Standards
Apoptosis
|
|
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
-
- HY-129440
-
-
-
- HY-N0103A
-
|
|
Infection
Alkaloids
Piperidine Alkaloids
Structural Classification
Classification of Application Fields
Leguminosae
Source classification
Sophora japonica L.
Plants
Inflammation/Immunology
Disease Research Fields
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
|
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
-
- HY-N0103
-
|
|
Infection
Alkaloids
Piperidine Alkaloids
Structural Classification
Classification of Application Fields
Leguminosae
Source classification
Sophora flavescens Aiton
Plants
Inflammation/Immunology
Disease Research Fields
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
PTEN
|
|
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
-
- HY-N0103R
-
|
|
Alkaloids
Piperidine Alkaloids
Structural Classification
Leguminosae
Source classification
Sophora flavescens Aiton
Plants
|
Reference Standards
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
|
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0114S
-
|
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-N0610AS
-
|
|
|
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
-
- HY-N0610AS2
-
|
|
|
Cinnamic acid- 13C3 (3-Phenylacrylic acid- 13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .
|
-
-
- HY-B0688S
-
|
|
|
Dapsone-d8 is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide antibiotic with antibacterial, antigenic and anti-inflammatory activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone can be used as an anticonvulsant and also in the research of skin and glioblastoma diseases .
|
-
-
- HY-B0114S2
-
|
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S1
-
|
|
|
Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S3
-
|
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-W747797
-
|
|
|
Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
-
- HY-B0106S
-
|
|
|
Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
-
- HY-B0106S1
-
|
|
|
Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
|
-
-
- HY-19939S
-
4 Publications Verification
|
|
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-153627
-
|
|
|
Alkynes
|
|
G13KS is a deubiquitinase UCHL1 ligand and inhibitor. G13KS inhibits recombinant and cellular UCHL1. G13KS reduces levels of monoubiquitin in human glioblastoma cells . GK13S is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-P10928
-
|
|
|
Azide
|
|
BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-115567
-
|
1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole
|
|
Nucleosides and their Analogs
|
|
5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model .
|
-
- HY-160056
-
|
|
|
Aptamers
|
|
GMT 5 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity .
|
-
- HY-160058
-
|
|
|
Aptamers
|
|
GMT 9 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity .
|
-
- HY-160054
-
|
|
|
Aptamers
|
|
GMT 3 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity .
|
-
- HY-160055
-
|
|
|
Aptamers
|
|
GMT 4 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity. GMT 4 aptamer sodium also shows high binding affinity to the T lymphocyte cell line CCRF-CEM .
|
-
- HY-160057
-
|
|
|
Aptamers
|
|
GMT 8 aptamer sodium is a nucleic acid aptamer targeting different glioblastoma cell lines and exhibits high affinity. GMT 4 aptamer sodium also shows high binding affinity to the T lymphocyte cell line CCRF-CEM .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
